Clinical trial
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal…
NCT00122317 · Alexion Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00122317 |
|---|---|
| Title | Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Official title | Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Paroxysmal Hemoglobinuria, Nocturnal |
| Intervention type | Drug |
| Interventions | eculizumab |
| Enrollment | 187 |
| Start date | May 1, 2005 |
| Primary completion | Sep 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Jul 22, 2005 |
| Last update posted | Mar 13, 2018 |
| Countries | Australia, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: